RecruitingEarly Phase 1NCT06629428

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People With Relapsing Multiple Sclerosis

Sponsor

Georgia State University

Enrollment

25 participants

Start Date

Nov 13, 2025

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis (MS) - Relapsing-remitting

Summary

The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a drug called ublituximab — which targets immune cells called B cells — can improve physical function and mobility in people with active, relapsing multiple sclerosis (MS). **You may be eligible if...** - You are between 18 and 55 years old - You have clinically confirmed active, relapsing MS - You can walk at least 25 feet (with or without a device) and stand for 30 seconds - You are not pregnant - You can read and understand English **You may NOT be eligible if...** - You have primary-progressive or inactive MS - You are pregnant, breastfeeding, or planning to become pregnant - You have a history of severe reactions to ublituximab or similar drugs - You have active hepatitis B, HIV, or other serious infections - You have significant heart disease or recent heart attack - You have had certain prior MS treatments (alemtuzumab, natalizumab, cladribine, etc.) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.